Gabapentin to Reduce Alcohol and Improve Viral Load Suppression - Promoting "Treatment as Prevention" - PROJECT SUMMARY / ABSTRACT
Ending the HIV epidemic requires achieving HIV viral load (HVL) suppression for key populations. Unhealthy
alcohol use by people with HIV (PWH) is a barrier to reaching HVL suppression at multiple stages of the HIV
care cascade. Alcohol use is common among PWH and results in lower antiretroviral therapy (ART) adherence
and HVL suppression, mitigating the effectiveness of Treatment as Prevention (TasP), a key strategy for
preventing HIV transmission. Treating alcohol use is therefore a mechanism to support PWH with unhealthy
alcohol use along the HIV care cascade. In fact, prior studies demonstrate that interventions to reduce alcohol
use positively impact HIV outcomes. Gabapentin is efficacious for decreasing alcohol consumption and may be
an effective treatment for painful conditions, such as HIV-associated sensory neuropathies. However,
gabapentin’s role in achieving HVL suppression in this population has not been established. Our hypothesis is
that effective pharmacological alcohol treatment (i.e., gabapentin) will help PWH engage in HIV care, adhere to
ART, and achieve HVL suppression. We propose the Gabapentin to Reduce Alcohol and Improve Viral Load
Suppression (GRAIL) randomized, double-blinded, placebo-controlled clinical trial to evaluate the efficacy of
gabapentin vs. placebo to achieve HVL suppression among PWH. The study population will be heavy drinkers
with HIV who had a detectable viral load in the past year, despite having been prescribed ART. Participants
(N=300) will be randomized 1:1 to receive either gabapentin (1800mg/day target dose) or placebo for 3
months; both arms will employ a one-time brief intervention to reduce alcohol use. GRAIL aims to 1) test the
efficacy of gabapentin versus placebo to achieve undetectable HVL at 3 months (primary outcome) and at 6 &
12 months (secondary outcomes); and 2) to assess the impact of gabapentin compared to placebo on: a)
alcohol consumption, b) pain severity, c) self-reported ART adherence, and d) engagement in HIV care, in
order to explore potential mechanisms by which gabapentin may lead to HVL suppression. This study will take
place in Russia, in a context of syndemic unhealthy alcohol use, drug use, and HIV. Our multi-disciplinary team
has an extensive track record of successfully conducting randomized clinical trials in Russia, including
pharmacological trials (e.g., gabapentin) in PWH. Russia, a setting in which HIV and heavy alcohol use are
more prevalent than in the US, will enable efficient study of intervening on alcohol use among PWH. The
knowledge gained will be applicable to populations living with HIV in the US and globally. The proposed trial of
gabapentin is significant as it employs a TasP approach to prevent transmission of HIV by targeting alcohol
use and achieving HVL suppression. If shown to be effective, this highly generalizable pragmatic approach to
TasP can be implemented in a variety of clinical settings, thus making it a practical addition to the HIV
prevention toolkit.
